Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel diseaseJ Schultheiss, Bas Oldenburg, Remi Mahmoud et al.|Alimentary Pharmacology & Therapeutics|2021Cited by 49
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, H. Schultheiss et al.|Clinical Gastroenterology and Hepatology|2022Cited by 31
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, Jeroen M. Jansen et al.|Clinical Gastroenterology and Hepatology|2022Cited by 18
Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov ModelRemi Mahmoud, Bas Oldenburg, Chris van Lieshout et al.|Journal of Crohn s and Colitis|2020Cited by 11
P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Journal of Crohn s and Colitis|2021Cited by 3